BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flores Á, Maldonado R, Berrendero F. The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward. Biol Psychiatry 2014;75:499-507. [PMID: 23896204 DOI: 10.1016/j.biopsych.2013.06.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Flores Á, Julià-Hernández M, Maldonado R, Berrendero F. Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol. Br J Pharmacol 2016;173:1381-92. [PMID: 26799708 DOI: 10.1111/bph.13440] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
2 Edalat P, Kavianpour M, Zarrabian S, Haghparast A. Role of orexin-1 and orexin-2 receptors in the CA1 region of hippocampus in the forced swim stress- and food deprivation-induced reinstatement of morphine seeking behaviors in rats. Brain Research Bulletin 2018;142:25-32. [DOI: 10.1016/j.brainresbull.2018.06.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
3 Pintwala S, Peever J. Circuit mechanisms of sleepiness and cataplexy in narcolepsy. Current Opinion in Neurobiology 2017;44:50-8. [DOI: 10.1016/j.conb.2017.02.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
4 Lopez MF, Moorman DE, Aston-Jones G, Becker HC. The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice. Brain Res 2016;1636:74-80. [PMID: 26851547 DOI: 10.1016/j.brainres.2016.01.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
5 Merlo Pich E, Melotto S. Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use. Front Neurosci 2014;8:26. [PMID: 24592206 DOI: 10.3389/fnins.2014.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
6 Berrendero F, Flores Á, Robledo P. When orexins meet cannabinoids: Bidirectional functional interactions. Biochemical Pharmacology 2018;157:43-50. [DOI: 10.1016/j.bcp.2018.08.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Asakura S, Shiotani M, Gauvin DV, Fujiwara A, Ueno T, Bower N, Beuckmann CT, Moline M. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant. Regul Toxicol Pharmacol 2021;127:105053. [PMID: 34619288 DOI: 10.1016/j.yrtph.2021.105053] [Reference Citation Analysis]
8 Owens B. With pot now legal, therapies sought to blunt high of marijuana. Nat Med 2014;20:107. [PMID: 24504393 DOI: 10.1038/nm0214-107] [Reference Citation Analysis]
9 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
10 Karimi S, Hamidi G, Fatahi Z, Haghparast A. Orexin 1 receptors in the anterior cingulate and orbitofrontal cortex regulate cost and benefit decision-making. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2019;89:227-35. [DOI: 10.1016/j.pnpbp.2018.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
11 Flores Á, Valls-Comamala V, Costa G, Saravia R, Maldonado R, Berrendero F. The hypocretin/orexin system mediates the extinction of fear memories. Neuropsychopharmacology 2014;39:2732-41. [PMID: 24930888 DOI: 10.1038/npp.2014.146] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
12 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
13 Azizi F, Fartootzadeh R, Alaei H, Reisi P. Effects of concurrent blockade of OX2 and CB1 receptors in the ventral tegmental area on nicotine-induced place preference in rats. Neuroscience Letters 2018;684:121-6. [DOI: 10.1016/j.neulet.2018.07.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Hiranita T. Self-Administration of JWH-018 A Synthetic Cannabinoid in Experimentally Naïve Rats. J Alcohol Drug Depend 2015;3:e128. [PMID: 27398395 DOI: 10.4172/2329-6488.1000e128] [Reference Citation Analysis]
15 Hiranita T. Self-Administration of an Endogenous Cannabinoid 2-Arachidonoylglycerol in Experimentally Naïve Rats. J Alcohol Drug Depend 2015;3:e126. [PMID: 27376099 DOI: 10.4172/2329-6488.1000e126] [Reference Citation Analysis]
16 Yazdi F, Jahangirvand M, Pirasteh A, Moradi M, Haghparast A. Functional interaction between OX2 and CB1 receptors in the ventral tegmental area and the nucleus accumbens in response to place preference induced by chemical stimulation of the lateral hypothalamus. Pharmacology Biochemistry and Behavior 2015;139:39-46. [DOI: 10.1016/j.pbb.2015.10.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
17 Zarrabian S, Riahi E, Karimi S, Razavi Y, Haghparast A. The potential role of the orexin reward system in future treatments for opioid drug abuse. Brain Research 2020;1731:146028. [DOI: 10.1016/j.brainres.2018.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
18 Barateau L, Jaussent I, Lopez R, Boutrel B, Leu-Semenescu S, Arnulf I, Dauvilliers Y. Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study. Sleep 2016;39:573-80. [PMID: 26564129 DOI: 10.5665/sleep.5530] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
19 Flores A, Maldonado R, Berrendero F. Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Front Neurosci 2013;7:256. [PMID: 24391536 DOI: 10.3389/fnins.2013.00256] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
20 Escudero-Lara A, Argerich J, Cabañero D, Maldonado R. Disease-modifying effects of natural Δ9-tetrahydrocannabinol in endometriosis-associated pain. Elife 2020;9:e50356. [PMID: 31931958 DOI: 10.7554/eLife.50356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
21 Steiner N, Rossetti C, Sakurai T, Yanagisawa M, de Lecea L, Magistretti PJ, Halfon O, Boutrel B. Hypocretin/orexin deficiency decreases cocaine abuse liability. Neuropharmacology 2018;133:395-403. [PMID: 29454841 DOI: 10.1016/j.neuropharm.2018.02.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
22 Mason BL, Mustafa A, Filbey F, Brown ES. Novel Pharmacotherapeutic Interventions for Cannabis Use Disorder. Curr Addict Rep 2016;3:214-20. [DOI: 10.1007/s40429-016-0094-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 D’addario C, Micioni Di Bonaventura M, Pucci M, Romano A, Gaetani S, Ciccocioppo R, Cifani C, Maccarrone M. Endocannabinoid signaling and food addiction. Neuroscience & Biobehavioral Reviews 2014;47:203-24. [DOI: 10.1016/j.neubiorev.2014.08.008] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 10.0] [Reference Citation Analysis]
24 Befort K. Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol 2015;6:6. [PMID: 25698968 DOI: 10.3389/fphar.2015.00006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
25 Brodnik ZD, Alonso IP, Xu W, Zhang Y, Kortagere S, España RA. Hypocretin receptor 1 involvement in cocaine-associated behavior: Therapeutic potential and novel mechanistic insights. Brain Res 2020;1731:145894. [PMID: 30071195 DOI: 10.1016/j.brainres.2018.07.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
26 Panagis G, Mackey B, Vlachou S. Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future. Front Psychiatry 2014;5:92. [PMID: 25132823 DOI: 10.3389/fpsyt.2014.00092] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
27 Ruiz CM, Torrens A, Castillo E, Perrone CR, Cevallos J, Inshishian VC, Harder EV, Justeson DN, Huestis MA, Swarup V, Piomelli D, Mahler SV. Pharmacokinetic, behavioral, and brain activity effects of Δ9-tetrahydrocannabinol in adolescent male and female rats. Neuropsychopharmacology 2021;46:959-69. [PMID: 32927465 DOI: 10.1038/s41386-020-00839-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
28 Kim HJJ, Zagzoog A, Smolyakova AM, Ezeaka UC, Benko MJ, Holt T, Laprairie RB. In vivo Evidence for Brain Region-Specific Molecular Interactions Between Cannabinoid and Orexin Receptors. Front Neurosci 2021;15:790546. [PMID: 34992518 DOI: 10.3389/fnins.2021.790546] [Reference Citation Analysis]